发明授权
US07576109B2 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof
失效
1,3,4-恶二唑-2-酮作为PPARδ调节剂及其用途
- 专利标题： 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof
- 专利标题（中）： 1,3,4-恶二唑-2-酮作为PPARδ调节剂及其用途
-
申请号： US11535227申请日： 2006-09-26
-
公开(公告)号： US07576109B2公开(公告)日： 2009-08-18
- 发明人: Daniel G. McGarry , Karen Chandross , Jean Merrill , Jochen Goerlitzer , Stefanie Keil , Wolfgang Wendler , Patrick Bernardelli
- 申请人： Daniel G. McGarry , Karen Chandross , Jean Merrill , Jochen Goerlitzer , Stefanie Keil , Wolfgang Wendler , Patrick Bernardelli
- 申请人地址： US NJ Bridgewater DE Frankfurt am Main
- 专利权人： Aventis Pharmaceuticals Inc.,Sanofi-Aventis Deutschland GmbH
- 当前专利权人： Aventis Pharmaceuticals Inc.,Sanofi-Aventis Deutschland GmbH
- 当前专利权人地址： US NJ Bridgewater DE Frankfurt am Main
- 代理商 Jiang Lin; Craig M. Bell
- 主分类号： A61K31/4245
- IPC分类号： A61K31/4245 ; C07D271/10 ; C07D413/10
摘要：
The present invention is directed to 1,3,4-oxadiazolones, compounds of formula I and their pharmaceutically acceptable salts stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein. The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization.
公开/授权文献
信息查询
